James Woods
Overview
Explore the profile of James Woods including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andersen A, Owens N, Murray A, Woods J, Prendergast A, Gurney J, et al.
Mil Med
. 2025 Mar;
PMID: 40037514
Background: The potential of large-scale future conflicts require expertise in field and facility-based care of high patient volumes in Prolonged Casualty Care scenarios. In our experience, a military-civilian partnership that...
2.
Zhuang X, Woods J, Ji Y, Scheich S, Mo F, Rajagopalan S, et al.
Cell Rep
. 2024 Apr;
43(4):114105.
PMID: 38619967
Natural killer (NK) cells are primary defenders against cancer precursors, but cancer cells can persist by evading immune surveillance. To investigate the genetic mechanisms underlying this evasion, we perform a...
3.
Pizzato H, Alonso-Guallart P, Woods J, Johannesson B, Connelly J, Fehniger T, et al.
Stem Cell Reports
. 2024 Mar;
19(4):596.
PMID: 38518782
No abstract available.
4.
Pizzato H, Alonso-Guallart P, Woods J, Connelly J, Fehniger T, Atkinson J, et al.
Stem Cell Reports
. 2024 Jan;
19(2):299-313.
PMID: 38215755
Successful allogeneic human pluripotent stem cell (hPSC)-derived therapies must overcome immunological rejection by the recipient. To build reagents to define these barriers, we genetically ablated β2M, TAP1, CIITA, CD74, MICA,...
5.
Pizzato H, Alonso-Guallart P, Woods J, Johannesson B, Connelly J, Fehniger T, et al.
bioRxiv
. 2023 Jul;
PMID: 37425790
Allogeneic human pluripotent stem cell (hPSC)-derived cells and tissues for therapeutic transplantation must necessarily overcome immunological rejection by the recipient. To define these barriers and to create cells capable of...
6.
Pennington K, McEwan C, Woods J, Muir C, Sahankumari A, Eastmond R, et al.
Mol Cancer Res
. 2021 Oct;
20(2):231-243.
PMID: 34654719
PTOV1 is an oncogenic protein, initially identified in prostate cancer, that promotes proliferation, cell motility, and invasiveness. However, the mechanisms that regulate PTOV1 remain unclear. Here, we identify 14-3-3 as...
7.
Almeida J, Shults N, De Souza A, Ji H, Wu X, Woods J, et al.
Exp Physiol
. 2020 May;
105(7):1172-1184.
PMID: 32410300
New Findings: What is the central question of this study? What are the effects of a 2 week period of severe food restriction on vascular reactivity of resistance arteries and...
8.
Zhang L, Zhen J, Huang Q, Liu H, Li W, Zhang S, et al.
Dev Dyn
. 2019 Dec;
249(4):543-555.
PMID: 31816150
Background: Intraflagellar transport is a motor-driven trafficking system that is required for the formation of cilia. Intraflagellar transport protein 20 (IFT20) is a master regulator for the control of spermatogenesis...
9.
Archer K, Reid E, Shizuka M, Woods J, Harris L, Maloney E, et al.
ACS Med Chem Lett
. 2019 Aug;
10(8):1211-1215.
PMID: 31413807
Indolinobenzodiazepine DNA alkylators (IGNs) are the cytotoxic payloads in antibody-drug conjugates (ADCs) currently undergoing Phase I clinical evaluation (IMGN779, IMGN632, and TAK164). These ADCs possess linkers that have been incorporated...
10.
Woods J
SLAS Discov
. 2019 Jun;
24(7):703-713.
PMID: 31173539
Camelid-derived nanobodies are versatile tools for research, diagnostics, and therapeutics. Certain nanobodies can function as intrabodies and bind antigens within the eukaryotic cytosol. This capability is valuable for the development...